Language: BG BG
← Back to results
Recruiting Phase 2 NCT06728579

Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors

Phase 2 – studying effectiveness and dosage
Conditions: Breast Cancer Survivor

Sponsor: Memorial Sloan Kettering Cancer Center

trial.available_in: БГ
Overview
The researchers are doing this study to compare two different types of group therapy and find out whether they are effective approaches for helping breast cancer survivors manage joint pain caused by aromatase inhibitors (AI). This type of joint pain is called AI-associated arthralgia, or AIA, and it is common in people taking AIs. AIA and its associated symptoms can make some people decide to stop taking their medication. The study will look at the effects of two different types of group therapy on participants' cancer-related symptoms (such as pain, fatigue, and anxiety), their ability to continue taking AIs on a regular schedule, and their quality of life. We will measure participants' quality of life by having them fill out questionnaires. Both groups will have 2-hour group therapy sessions once a week, over the course of 8 weeks. During the sessions, you will be in a group of 6-10 participants, who may be a mixture of patients from both MSK and University of California San Diego (UCSD).
Who can participate
Inclusion Criteria: * Age ≥18 years * English-proficient women with a history of stage I, II, or III breast cancer * Free of oncologic disease by clinical examination and history; * Receiving third-generation AI therapy (anastrozole, letrozole, or exemestane) for at least 28 days prior to consent with plan to continue for at least another 12 months; * Worst joint pain rated at least 4 or greater on a 0-10 numeric rating scale in the preceding week prior to consent; * Reporting at least 15 days with pain in the preceding 30 days prior to consent; * Experiencing joint pain for at least one month; * Pain attributed to AI therapy; * Willing to adhere to all study-related procedures, including randomization to one of two treatment arms: Mindfulness-Oriented Recovery Enhancement (MORE) or Supportive Group Psychotherapy (SG); * Able to attend video-call sessions in a quiet/private location. Exclusion Criteria: * Metastatic breast cancer (stage IV); * Completed chemotherapy, surgery, or radiation therapy less than 4 weeks prior to enrollment; * Pain attributed to inflammatory arthritis (i.e. rheumatoid arthritis, gout, pseudogout); * Surgery or joint injection involving the affected joints within the last month or planned within the next six months; * Active suicidality or psychosis as determined by the Mini-International Neuropsychiatric Interview.
Interventions
Mindfulness Oriented Recovery Enhancement (MORE)
BEHAVIORAL
Questionnaires
OTHER
Supportive Psychotherapy (SG)
BEHAVIORAL
Locations 9
United States (9)
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge , New Jersey
Jun Mao, MD, MSCE
Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities)
Commack , New York
Jun Mao, MD, MSCE
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison , New York
Jun Mao, MD, MSCE
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown , New Jersey
Jun Mao, MD, MSCE
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale , New Jersey
Jun Mao, MD, MSCE
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York , New York
Jun Mao, MD, MSCE
University of California San Diego (Data collection and Data analysis)
San Diego , California
Eric Garland, PhD, LCSW
Florida State University
Tallahassee , Florida
NOT_YET_RECRUITING
Adam Hanley, PhD
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale , New York
Jun Mao, MD, MSCE
Technical details
Status
Recruiting
Phase
Phase 2
Study type
INTERVENTIONAL
Sex
Female only
Minimum age
18 Years
Healthy volunteers
No
Start date
06.12.2024
Completion date
01.12.2028
Registry ID
NCT06728579
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.